PCM
AUPH icon

Prelude Capital Management’s Aurinia Pharmaceuticals AUPH Stock Holding History

Prelude Capital Management’s Portfolio AUPH Stock Details AUPH Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q1 		– Sell
-3,800
Closed -$77K – 1435
2019
Q4 		$77K Buy
+3,800
New +$35K ﹤0.01% 1193

Other funds holding AUPH

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return
NMC
NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
N
Nuveen Charlotte, North Carolina $369B AUM 31.66% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Prelude Capital Management's AUPH Position: Q3 2023 in Review

Prelude Capital Management sold out of Aurinia Pharmaceuticals (AUPH) in Q3 2023, closing a stake of 15,395 shares — an estimated $149K sold.

Prelude Capital Management first reported a position in AUPH in Q1 2023 and held it in 2 quarters. The position peaked at $171K in Q1 2023. 198 funds tracked by Wall St. Rank hold AUPH as of Q3 2023.

  • Prelude Capital Management reported no remaining Aurinia Pharmaceuticals position as of Q3 2023 after selling out during the quarter.
  • Prelude Capital Management sold 15,395 Aurinia Pharmaceuticals shares in Q3 2023, an estimated $149K.
  • Prelude Capital Management first reported a position in Aurinia Pharmaceuticals in Q1 2023 and held it in 2 quarters.
  • Prelude Capital Management's Aurinia Pharmaceuticals position peaked at $171K in Q1 2023.
  • 198 funds tracked by Wall St. Rank held Aurinia Pharmaceuticals as of Q3 2023.

Based on Prelude Capital Management's 13F filing for Q3 2023, filed 14 Nov 2023.